Investors & Media

Corporate Overview

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune Stimulating Antibody Conjugate (ISAC) clinical candidate targeting Claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of 6 different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies.

News

September 4, 2024

Bolt Biotherapeutics Announces Changes to its Board of DirectorsRead More

August 28, 2024

Bolt Biotherapeutics to Participate in Upcoming September ConferencesRead More

August 13, 2024

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateRead More

View All News Releases

Events

September 9, 2024 at 7:00 AM EDT

H.C. Wainwright 26th Annual Global Investment Conference Read More

September 6, 2024 at 7:00 AM EDT

Morgan Stanley 22nd Annual Global Healthcare Conference Read More

May 14, 2024 at 4:30 PM EDT

Bolt Biotherapeutics Q1 2024 Strategic Update Call Read More

View All Upcoming Events